Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Operating Expenses (2018 - 2025)

Lineage Cell Therapeutics (LCTX) has 13 years of Other Operating Expenses data on record, last reported at $66000.0 in Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 57.14% year-over-year to $66000.0; the TTM value through Dec 2025 reached $15.0 million, up 4386.83%, while the annual FY2025 figure was $15.0 million, 4386.83% up from the prior year.
  • Other Operating Expenses reached $66000.0 in Q4 2025 per LCTX's latest filing, up from $5000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $14.9 million in Q2 2025 and bottomed at -$4.4 million in Q4 2022.
  • Average Other Operating Expenses over 5 years is $1.6 million, with a median of $82000.0 recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: crashed 100.01% in 2022, then soared 33715.91% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $8.1 million in 2021, then crashed by 153.79% to -$4.4 million in 2022, then skyrocketed by 103.87% to $169000.0 in 2023, then fell by 8.88% to $154000.0 in 2024, then crashed by 57.14% to $66000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $66000.0 in Q4 2025, $5000.0 in Q3 2025, and $14.9 million in Q2 2025.